Intuitive Surgical (1ISRG) Price & Analysis

15 Followers

1ISRG Stock Chart & Stats

€316.10

€8.80(3.03%)

At close: Jul 24 4:00 PM EDT

€316.10

€8.80(3.03%)

Day’s Range― - ―

52-Week Range€290.20 - €744.00

Previous CloseN/A

Volume16.00

Average Volume (3M)33.00

Market Cap

€125.67B

Enterprise Value€136.97K

Total Cash (Recent Filing)€5.22B

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)45.8

Beta0.52

Next Earnings

Oct 20, 2026

EPS Estimate

2.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)8.85

Shares Outstanding353,278,050

10 Day Avg. Volume30

30 Day Avg. Volume33

Financial Highlights & Ratios

PEG Ratio3.17

Price to Book (P/B)11.34

Price to Sales (P/S)20.08

P/FCF Ratio81.16

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€430.13

Price Target Upside36.07% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering22

EPS Forecast (FY)9.36

Revenue Forecast (FY)€10.19B

Bulls Say, Bears Say

Bulls Say

Recurring Revenue And Installed BaseThe large installed base creates an expanding foundation for recurring instruments, accessories, and service revenue. With recurring revenue already representing most sales, continued system placements and procedure growth can improve revenue visibility and support durable customer relationships.

Strong Cash Generation And Balance SheetStrong free cash flow and substantial liquidity give Intuitive flexibility to fund research, product development, customer support, and expansion without relying heavily on debt. This financial resilience can help sustain investment through changing procedure volumes and capital-spending conditions.

Product Innovation And Clinical AdoptionOngoing product upgrades and regulatory submissions broaden Intuitive’s technology platform beyond its established systems. Progress in visualization, workflow, training, and additional robotic applications can support adoption across specialties and care settings over the medium term.

Bears Say

China Market And Pricing PressureWeak tender activity and stronger domestic competition constrain system placements in China, while policy-driven pricing pressure can reduce the economics of that market. The lack of da Vinci 5 clearance there also limits the near-term product opportunity and regional growth contribution.

Extended-Use Instruments May Reduce Recurring RevenueThe extended-use program could improve customer economics and support adoption, but it may also reduce replacement frequency or revenue per procedure for instruments and accessories. Because the company has not quantified the effect, recurring-revenue durability remains exposed to rollout and utilization outcomes.

Growth Deceleration And Cost PressuresA slower growth profile can make it harder to absorb rising operating expenses and input costs through scale. Although profitability remains strong, continued deceleration would reduce operating leverage and place greater importance on sustained procedure growth, placements, and disciplined spending.

Intuitive Surgical News

Overvalued Healthcare Stocks? Analysts See Upside in These 3 High P/E Names

Using the TipRanks Stock Screener tool, we identified three Healthcare stocks with P/E ratios ranging from 39.58x to 43.34x, Strong Buy...

9d ago

ALNY

BTSG

3 Healthcare Stocks with More Than 20% Upside and Recent Buy Ratings

Eli Lilly ($LLY), UnitedHealth Group ($UNH), and Intuitive Surgical ($ISRG) have each received Buy ratings from Wall Street...

11d ago

LLY

UNH

Healthcare Costs Are Rising Twice as Fast as Everything Else: Inside Milliman’s Healthcare Inflation ETFs (MHIG, MHIP)

U.S. healthcare costs are climbing more than 7% a year, over double broad inflation, and most portfolios hold...

13d ago

JNJ

LLY

SS Innovations International (NASDAQ: SSII) Highlighted as Stronger Growth Opportunity in Seeking Alpha Analysis

Austin, Texas, United States, September 2nd, 2026, FinanceWire SS Innovations International (NASDAQ:SSII) was highlighted in a Seeking Alpha analysis...

25d ago

ISRG

SSII

Trump Trade: Canada rolls out 50% tariffs on U.S. metals

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

1M ago

HHS plans to add FDA deputy roles for technology, drugs, CNBC says

The Department of Health and Human Services is planning to create two new deputy commissioner roles at the...

1M ago

ABT

BMY

Unitree Crypto Futures Signal 300% Price Jump Ahead of Humanoid Robot Maker’s Listing

Crypto futures contracts tracking Unitree Robotics are telling us to expect a 300% price jump ahead of the...

1M ago

TER

ISRG

Intuitive Surgical upgraded to Outperform from Perform at Oppenheimer

Oppenheimer upgraded Intuitive Surgical (ISRG) to Outperform from Perform. Published first on TheFly – the ultimate source for...

1M ago

ISRG

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

Oppenheimer upgraded Intuitive Surgical (ISRG) to Outperform from Perform with a $500 price target. Field checks suggest workflow...

1M ago

JNJ

ISRG

Okta upgraded, Gap downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

BSP

GAP

These 2 ‘Strong Buy’ Stocks Are Worth Buying on the Dip, Say Analysts

Buying the dip remains one of the market’s most popular investing strategies, particularly when quality stocks suffer meaningful...

1M ago

TPG

ISRG

Intuitive Surgical’s ENCOMPASS Trial Puts Robotic Lung Biopsy in the Spotlight

Intuitive Surgical ($ISRG) announced an update on their ongoing clinical study. The ENCOMPASS trial is a new post-market...

2M ago

ISRG

Intuitive Surgical: Buy Rating Reiterated as New GI Platform Progress Supports Growth; $685 Price Target Maintained

Bernstein analyst Lee Hambright maintained a Buy rating on Intuitive Surgical yesterday and set a price target of...

2M ago

ISRG

Analyst Reiterates Buy on Intuitive Surgical, Seeing Johnson & Johnson’s Ottava as a Growth Catalyst Rather Than a Competitive Threat

TD Cowen analyst Mathew Blackman maintained a Buy rating on Intuitive Surgical yesterday and set a price target...

2M ago

ISRG

1ISRG FAQ

What was Intuitive Surgical’s price range in the past 12 months?

Intuitive Surgical lowest stock price was €290.20 and its highest was €744.00 in the past 12 months.

What is Intuitive Surgical’s market cap?

Intuitive Surgical’s market cap is €125.67B.

When is Intuitive Surgical’s upcoming earnings report date?

Intuitive Surgical’s upcoming earnings report date is Oct 20, 2026 which is in 23 days.

How were Intuitive Surgical’s earnings last quarter?

Intuitive Surgical released its earnings results on Jul 16, 2026. The company reported €2.405 earnings per share for the quarter, beating the consensus estimate of €2.157 by €0.248.

Is Intuitive Surgical overvalued?

According to Wall Street analysts Intuitive Surgical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Intuitive Surgical pay dividends?

Intuitive Surgical does not currently pay dividends.

What is Intuitive Surgical’s EPS estimate?

Intuitive Surgical’s EPS estimate is 2.27.

How many shares outstanding does Intuitive Surgical have?

Intuitive Surgical has 353,278,050 shares outstanding.

What happened to Intuitive Surgical’s price movement after its last earnings report?

Intuitive Surgical reported an EPS of €2.405 in its last earnings report, beating expectations of €2.157. Following the earnings report the stock price went down -12.241%.

Which hedge fund is a major shareholder of Intuitive Surgical?

Currently, no hedge funds are holding shares in IT:1ISRG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Intuitive Surgical Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

3.54%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Intuitive Surgical

Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.

Intuitive Surgical (1ISRG) Earnings & Revenues

Historic Earnings Reports

1ISRG Company Deck

1ISRG Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presented a predominantly positive operational and financial picture: robust revenue (+19%), strong profitability (42% non-GAAP operating margin), healthy procedure growth (total +16%) and capital placements (468 da Vinci systems), plus strong cash flow. The company also highlighted meaningful product progress (da Vinci 5 updates, SP and XiR momentum, ION adoption) and clinical evidence supporting adoption. Key risks were noted but were mostly market- and policy-driven (U.S. patient coverage dynamics, China tender and pricing pressure), some procedure-mix headwinds (bariatrics) and an unquantified impact from the extended-use instrument program. Overall, the positive metrics and growth drivers materially outweigh the challenges discussed.View all IT:1ISRG earnings summaries

1ISRG Revenue Breakdown

67.72% U.S.

32.28% Outside of U.S

1ISRG Stock 12 Month Forecast

Average Price Target

€430.13

▲(36.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"303":"€303","602":"€602","377.75":"€377.8","452.5":"€452.5","527.25":"€527.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":601.36883635,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€601.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":430.1300420731579,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€430.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":343.26308761,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€343.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[303,377.75,452.5,527.25,602],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,317.85,339.65914125769234,361.46828251538466,383.277423773077,405.0865650307693,426.8957062884616,448.70484754615387,470.5139888038462,492.3231300615385,514.1322713192308,535.9414125769231,557.7505538346154,579.5596950923077,{"y":601.36883635,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,317.85,326.4869263133199,335.1238526266397,343.76077893995955,352.39770525327936,361.0346315665992,369.671557879919,378.3084841932389,386.9454105065587,395.58233681987855,404.21926313319835,412.8561894465182,421.493115759838,{"y":430.1300420731579,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,317.85,319.80485289307694,321.75970578615386,323.7145586792308,325.6694115723077,327.6242644653846,329.57911735846153,331.5339702515385,333.4888231446154,335.44367603769234,337.39852893076926,339.3533818238462,341.3082347169231,{"y":343.26308761,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":404.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":370.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":462.45,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":490.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":486.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":423.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":422.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.25,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":361.65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355.95,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304.45,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":317.85,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >